Juvenile Arthritis News

The key elements that guide the diagnosis of chronic idiopathic musculoskeletal pain do not primarily come from physical exam, but from the patient’s history of pain and the physician’s opinion, according to findings published in Pediatric Rheumatology.

Among patients with well-controlled juvenile idiopathic arthritis, and their caregivers, when and how they decide to discontinue treatment likely depends on whether they are more concerned with disease- or treatment-related complications, and often involves a “trade-off” between these competing risks, according to survey findings published in Arthritis Care & Research.

Among patients with rheumatic diseases, treatment with any biologic increases the risk for tuberculosis, both reactivation and new-onset, with an incidence rate among biologic users that is 10 times higher in South Africa than in European countries, according to data published in Annals of the Rheumatic Diseases.

The rheumatology community lost clinician and educator Calvin R. Brown, MD, on Dec. 1, 2019. He was 66 years old. His final years were spent at the Northwestern University Feinberg School of Medicine, practicing rheumatology and training fellows in the specialty.

Officials from the Nebraska Department of Health and Human Services have issued a public health advisory following multiple reports of serious adverse events in patients who were treated with unapproved stem cell products, particularly those marketed as containing exosomes.

When journalist Ben Hammersley coined the word “podcast” in 2004, he was attempting to put a name to the phenomenon resulting from the timely convergence of widely available MP3 player technology, inexpensive audio software and weblog culture — a renaissance of radio programs that could be downloaded and played at the listener’s convenience, anytime or anywhere.

ATLANTA — Patients with Down syndrome arthropathy experience a year-long delay from symptom onset to diagnosis, according to a presentation at the 2019 ACR/ARP Annual Meeting.

ATLANTA — Systemic juvenile idiopathic arthritis with macrophage activation syndrome was marked by elevated adenosine deaminase 2 levels, according to a speaker at ACR/ARP 2019.

ATLANTA — Lax FDA policies on required pediatric studies for approved biologic DMARDs have exacerbated an already critical lack of approved therapies for juvenile idiopathic arthritis and related conditions, according to a presentation at the 2019 ACR/ARP Annual Meeting.

Children with inflammatory bowel disease, juvenile idiopathic arthritis and chronic noninfectious osteomyelitis had an increased rate of psoriasis, and those exposed to tumor necrosis factor inhibitor therapy exhibited the highest risk, according to research presented at the American College of Rheumatology/Association of Rheumatology Professionals annual meeting.